Drugs / ERY-ASP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01523808 | Nov 2009 → Mar 2011 | malignant pancreatic neoplasm | ERYtech Pharma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ERY-ASP | “Asparaginase encapsulated in erythrocytes (ERY-ASP) is a potentially effective drug in patients with pancreatic adenocarcinoma (PAC) with null/low asparagine synthetase (ASNS)...” PMID 26355551 ↗ Oct 2015 |
| Modality | Protein / enzyme biologic | “Asparaginase encapsulated in erythrocytes (ERY-ASP) is a potentially effective drug” PMID 26355551 ↗ Oct 2015 |